ALPHA TEKNOVA INC
TKNO · NASDAQ
Updated at 2026-10-15 06:44:56
- Today's High
- $8.29
- Today’s Low
- $7.77
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $8.15
- Previous Close
- $7.79
- Volume
- 236.32K
- Market Cap
- $418.23M
- P/E Ratio
- --
- EPS
- $-0.31
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Life Sciences Tools & Services
- Sub-industry
- DRUG MANUFACTURERS - SPECIALTY & GENERIC
- Headquarters
- 2451 BERT DR., HOLLISTER, CA, UNITED STATES, 95023
- Country
- US
- Listing Date
- 2021-06-25
- Fiscal Year End
- December
- Shares Outstanding
- 53.61M
- CIK
- 0001850902
- Website
- www.teknova.com
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
Financial Metrics
Revenue
2026-06-30
$12.18M
2026-03-31
$11.07M
2025-12-31
$9.98M
2025-09-30
$10.45M
Operating Expenses
2026-06-30
$7.77M
2026-03-31
$7.79M
2025-12-31
$7.85M
2025-09-30
$7.22M
Net Income
2026-06-30
-$3.17M
2026-03-31
-$4.55M
2025-12-31
-$4.75M
2025-09-30
-$4.28M
Net Profit Margin
2026-06-30
-26.01%
2026-03-31
-41.12%
2025-12-31
-47.65%
2025-09-30
-40.99%
Earnings Per Share
2026-06-30
$-0.06
2026-03-31
$-0.08
2025-12-31
$-0.09
2025-09-30
$-0.08
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1.29M
2026-03-31
-$2.71M
2025-12-31
-$3.02M
2025-09-30
-$2.42M
Effective Tax Rate
2026-06-30
-0.95%
2026-03-31
-1.04%
2025-12-31
1.28%
2025-09-30
-1.87%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $12.18M | $11.07M | $9.98M | $10.45M |
| Operating Expenses | $7.77M | $7.79M | $7.85M | $7.22M |
| Net Income | -$3.17M | -$4.55M | -$4.75M | -$4.28M |
| Net Profit Margin | -26.01% | -41.12% | -47.65% | -40.99% |
| Earnings Per Share | $-0.06 | $-0.08 | $-0.09 | $-0.08 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1.29M | -$2.71M | -$3.02M | -$2.42M |
| Effective Tax Rate | -0.95% | -1.04% | 1.28% | -1.87% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.